KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior. The findings, published in Science Translational Medicine, could lead to personalized therapies based on the KRAS mutation type.
This article was originally published on MedicalXpress.com
